Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 15, 2005 - Issue 4
Submit an article Journal homepage
86
Views
22
CrossRef citations to date
0
Altmetric
Review

NR2B subtype-selective NMDA receptor antagonists: 2001 – 2004

John A McCauley Department of Medicinal Chemistry, Merck Research Laboratories, WP14-3, West Point, PA 19486, USA. [email protected]
Pages 389-407 | Published online: 22 Apr 2005

Bibliography

  • MADDEN DR: The structure and function of glutamate receptor ion channels. Nat. Rev. Neurosci. (2002) 3 (2) :91–101.
  • DINGLEDINE R, BORGES K, BOWIE D, TRAYNELIS SF: The glutamate receptor ion channels. Pharmacol. Rev. (1999) 51(1):7–61.
  • LYNCH DR, GUTTMAN RP: NMDA receptor pharmacology: perspectives from molecular biology. Curr. Drug Targets (2001) 2(3):215–231.
  • PARSONS CG, DANYSZ W, QUACK G: Glutamate in CNS disorders as a target for drug development: an update. Drug News Perspect. (1998) 11(9):523–579.
  • A comprehensive review of the role of glutamate receptors in CNS disorders with 750 references.
  • PALMER GC: Neuroprotection by NMDA receptor antagonists in a variety of neuropathologies. Curr. Drug Targets (2001) 2(3):241–271.
  • An extensive review of pre-clinical and clinical studies with NMDA receptor antagonists.
  • LE DA, LIPTON SA: Potential and current use of N-methyl-D-aspartate (NMDA) receptor antagonists in diseases of aging. Drugs Aging (2001) 18(10):717–724.
  • SMITH PF: Therapeutic N-methyl-D-aspartate receptor antagonists: will reality meet expectation? Curr. Opin. Invest. Drugs (2003) 4(7):826–832.
  • HOCKING G, COUSINS MJ: Ketamine in chronic pain management: an evidence-based review. Anesth. Analg. (2003) 97(6):1730–1739.
  • FERRIS SH: Evaluation of memantine for the treatment of Alzheimer's disease. Expert Opin. Pharmacother. (2003) 4(12):2305–2313.
  • LIPTON SA, CHEN H-SV: Paradigm shift in neuroprotective drug development: clinically tolerated NMDA receptor inhibition by memantine. Cell Death Differ. (2004) 11(1):18–20.
  • SUGIHARA H, MORIYOSHI K, ISHII T, MASU M, NAKANISHI S: Structures and properties of seven isoforms of NMDA receptor generated by alternative splicing. Biochem. Biophys. Res. Commun. (1992) 185(3):826–832.
  • CULL-CANDY S, BRICKLEY S, FARRANT M: NMDA receptor subunits: diversity, development and disease. Curr. Opin. Neurobiol (2001) 11(3):327–335.
  • CHATTERTON JE, AWOBULUYI M, PREMKUMAR LS et al.: Excitatory glycine receptor containing the NR3 family of NMDA receptor subunits. Nature (2002) 415(6873):793–798.
  • MONYER H, BURNASHEV N, LAURIE DJ, SAKMANN B, SEEBURG PH: Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron (1994) 12(3):529–540.
  • WILLIAMS K: Ifenprodil discriminates subtypes of the N-methyl-D-aspartate receptor: selectivity and mechanism at recombinant heteromeric receptors. Md. PharmacoL (1993) 44(4):851–859.
  • BOYCE S, WYATT A, WEBB JK et al.: Selective NMDA NR2B antagonists induce antinociception without motor dysfunction: correlation with restricted localization of NR2B subunit in dorsal horn. Neuropharmacology (1999) 38(5):611–623.
  • LOFTIS JM, JANOWSKY A: The N-methyl-D-aspartate receptor subunit NR2B: localization, functional properties, regulation, and clinical applications. Pharmacol Thera)). (2003) 97(1):55–85.
  • A detailed review of NR2B subunit structure and function.
  • MALHERBE P, MUTEL V, BROGER C et al.: Identification of critical residues in the amino terminal domain of the human NR2B subunit involved in the Ro 25-6981 binding pocket. J. PharmacoL Exp. Ther. (2003) 307(3):897–905.
  • GIBB AJ: NMDA receptor subunit gating - uncovered. Trends Neurosci. (2004) 27(1):7–10.
  • BANKE TG, TRAYNELIS SF: Activation of NR1/NR2B NMDA receptors. Nat. Neurosci. (2003) 6(2):144–152.
  • CHAZOT PL, LAWRENCE S, THOMPSON CL: Studies on the subtype selectivity of CP-101,606: evidence for two classes of NR2B-selective NMDA receptor antagonists. Neuropharmaco/ogy (2002) 42(3):319–324.
  • CHENARD BL, BORDNER J, BUTLER TW et al.: (1S,2S)-1-(4-Hydroxypheny1)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol: a potent new neuroprotectant which blocks N-methyl-D-aspartate responses. J. Med. Chem. (1995) 38(16):3138–3145.
  • FISCHER G, MUTEL V, TRUBE G et al.: Ro 25-6981, a highly potent and selective blocker of N-methyl-D-aspartate receptors containing the NR2B subunit. Characterization in vitro. J. PharmacoL Exp. Ther. (1997) 283(3):1285–1292.
  • TANG Y-P, SHIMIZU E, DUBE GR et aL: Genetic enhancement of learning and memory in mice. Nature (1999) 401(6748):63–69.
  • DOYLE KM, FEERICK S, KIRKBY DL, EDDLESTON A, HIGGINS GA: Comparison of various N-methyl-D-aspartate receptor antagonists in a model of short-term memory and on overt behavior. Behav. PharmacoL (1998) 9(8):671–681.
  • GUSCOTT MR, CLARKE HF, MURRAY F, GRIM WOOD S, BRISTOW LJ, HUTSON PH: The effect of (±)-CP-101,606, an NMDA receptor NR2B subunit selective antagonist, in the Morris watermaze. Eur. J. PharmacoL (2003) 476(3):193–199.
  • GILL R, ALANINE A. BOURSON B et al.: Pharmacological characterization of Ro 63–1908 (1-12-(4-hydroxy-phenoxy)-ethy11-4-(4-methyl-benzyfi-piperidin-4-ol), a novel subtype-selective N-methyl-D-aspartate antagonist. J. Pharmacol. Exp. Ther. (2002) 302(3):940–948.
  • HIGGINS GA, BALLARD TM, HUWYLER J, KEMP JA, GILL R: Evaluation of the NR2B-selective NMDA receptor antagonist Ro 63-1908 on rodent behaviour: evidence for an involvement of NR2B NMDA receptors in response inhibition. Neuropharmaedogy (2003) 44(3):324–341.
  • ZHOU Z-L, CAI SX, WHITTEMORE ER et al.: 4-Hydroxy-1-12-(4-hydroxyphenoxy)ethyll-4-(4-methylbenzyfipiperidine: A novel, potent, and selective NR1/2B NMDA receptor antagonist. J. Med. Chem. (1999) 42(15):2993–3000.
  • PARSONS CG: NMDA receptors as targets for drug action in neuropathic pain. Eur. J. PharmacoL (2001) 429(1-3):71–78.
  • CHIZH BA: Novel approaches to targeting glutamate receptors for the treatment of chronic pain: review article. Amino Acids (2002) 23(1-3):169–176.
  • PETRENKO AB, YAIVIAKURA T, BABA H, SHIMOJI K: The role of N-methyl-D-aspartate (NMDA) receptors in pain: a review: Anesth. Analg (2003) 97(4):1108–1116.
  • GURWITZ D, WEIZMAN A: The NR2B subunit of glutamate receptors as a potential target for relieving chronic pain: prospects and concerns. Drug Discov. Today (2002) 7(7):403–406.
  • TANIGUCHI K, SHINJO K, MIZUTANI M et al.: Antinociceptive activity of CP-101,606, an NMDA receptor NR2B subunit antagonist. Br. J. PharmacoL (1997) 122(5):809–812.
  • CHIZH BA, HEADLEY PM, TZSCHENTKE TM: NMDA receptor antagonists as analgesics: focus on the NR2B subtype. Trends PharmacoL Sci. (2001) 22(12):636–642.
  • A review of work with NR2B receptor antagonists as analgesics.
  • KEMP JA, MCKERNAN RM: NMDA receptor pathways as drug targets. Nat. Neurosci. (2002) 5(suppl.):1039-1042. An excellent discussion of the potential of NMDA antagonists as therapeutic agents.
  • CHAZOT PL: The NMDA receptor NR2B subunit: a valid therapeutic target for multiple CNS pathologies. Curr. Med. Chem. (2004) 11(3):389–396.
  • An extensive review of NR2B receptor structure and function, SAR of ifenprodil analogues and the potential therapeutic uses of NR2B-selective NMDA receptor antagonists.
  • NASH JE, HILL MP, BROTCHIE JM: Antiparkinsonian actions of blockade of NR2B-containing NMDA receptors in the reserpine-treated rat. Exp. NeuroL (1999) 155(1):42–48.
  • MARINO M, VALENTI 0, CONN PJ: Glutamate receptors and Parkinson's disease: opportunities for intervention. Drugs Aging (2003) 20(5):377–397.
  • NASH JE, FOX SH, HENRY B et al.: Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease. Exp. NeuroL (2000) 165(1):136–142.
  • STEECE-COLLIER K, CHAMBERS LK, JAW-TSAI SS, MENNITI, FS, GREENMYRE JT: Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-D-aspartate receptors. Exp. NeuroL (2000) 163(1):239–243.
  • LOSCHMANN P-A, DE GROOTE C, SMITH Let al.: Antiparkinsonian activity of Ro 25–6981, a NR2B subunit specific NMDA receptor antagonist, in animal models of Parkinson's disease. Exp. NeuroL (2004) 187(1):86–93.
  • NASH JE, RAVENSCROFT P, MCGUIRE S, CROSSMAN AR, MENNITI FS, BROTCHIE JM: The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease. Exp. Neurol. (2004) 188(2):471–479.
  • WESSEL RH, AHMED SM, MENNITI FS, DUNBAR GL, CHASE TN, OH JD: NR2B selective NMDA receptor antagonist CP-101,606 prevents levodopa-induced motor response alterations in hemi-parkinsonian rats. Neuropharmacology (2004) 47(2):184–194.
  • HADJ TAHAR A, GREGOIRE L, DARRE A, BELANGER N, MELTZER L, BEDARD PJ: Effect of a selective glutamate antagonist on L-dopa-induced dyskinesias in drug-naive parkinsonian monkeys. NeurobioL Dis. (2004) 15(2):171–176.
  • BLANCHET PJ, KONITSIOTIS S, WHIF1EMORE ER, ZHOU ZL, WOODWARD RM, CHASE TN: Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methy1-4-phenyl-tetrahydropyridine monkeys. J. PharmacoL Exp. Ther. (1999) 290(3):1034–1040.
  • BLANCHET PJ, CALON F, MORISSE Fl M et aL: Relevance of the MPTP primate model in the study of dyskinesia priming mechanisms. Parkinsonism ReL Dis. (2004) 10(5):297–304.
  • BARTON ME, WHITE HS: The effect of CGX-1007 and CI-1041, novel NMDA receptor antagonists, on kindling acquisition and expression. Epilepsy Res. (2004) 59(1):1–12.
  • KOHL BK, DANNHARDT G: The NMDA receptor complex: a promising target for novel antiepileptic strategies. Curr. Med. Chem. (2001) 8(11):1275–1289.
  • NAGY J, HORVATH C, FARKAS S, KOLOK S, SZOMBATHELYI Z: NR2B subunit selective NMDA antagonists inhibit neurotoxic effect of alcohol-withdrawal in primary cultures of rat cortical neurones. Neurochem. Int. (2004) 44(1):17–23.
  • NAGY J: Renaissance of NMDA receptor antagonists: do they have a role in the pharmacotherapy for alcoholism? Invest. Drugs J. (2004) 7(4):339–350.
  • ALBERCH J, CANALS JM, PÉREZ-NAVARRO E: Therapeutic strategies in Huntington's disease. Expert Opin. Ther. Patents (2003) 13(4):449–465.
  • WOOD PL, HAWKINSON JE: N-methyl-D-aspartate antagonists for stroke and head trauma. Expert Opin. Investig: Drugs (1997) 6(4):389–397.
  • PEDERSEN V, SCHMIDT WJ: The neuroprotectant properties of glutamate antagonists and antiglutamatergic drugs. Neurotox. Res. (2000) 2(2-3):179–204.
  • WILLIAMS AJ, DAVE JR, LU XM, LING G, TORTELLA FC: Selective NR2B NMDA receptor antagonists are protective against staurosporine-induced apoptosis. Eur. J. Pharmacol (2002) 452(1):135–136.
  • HYND MR, SCOTT HL, DODD PR: Differential expression of N-methyl-D-aspartate receptor NR2 isoforms in Alzheimer's disease. J. Neurochem. (2004) 90(4):913–919.
  • CHOI DW: Exploratory clinical testing of neuroscience drugs. Nat. Neurosci. (2002) 5(suppl.):1023–1025.
  • MERCHANT RE, BULLOCK MR, CARMACK CA et al.: A double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of CP-101,606 in patients with a mild or moderate traumatic brain injury. Ann. NY Acad. Sci. (1999) 890:42–50.
  • BULLOCK MR, MERCHANT RE, CARMACK CA et al.: An open-label study of CP-101,606 in subjects with a severe traumatic head injury or spontaneous intracerebral hemorrhage. Ann. NY Acad. Sci. (1999) 890:51–58.
  • SANG CN, WEAVER JJ, JINGA L,WOUDEN J, SALTARELLI MD: The NR2B subunit-selective NMDA receptor antagonist, CP-101,606, reduces spontaneous pain intensity in patients with central and peripheral neuropathic pain. Program No. 814.9.2003 Abstract Viewer/Itinerary Planner. Washington, DC. Society for Neuroscience (2003) online.
  • CHENARD BL, MENNITI FS: Antagonists selective for NMDA receptors containing the NR2B subunit. Curr. Pharm. Des. (1999) 5(5):381–404.
  • ••An excellent review of early NR2Bantagonist medicinal chemistry research and SAR.
  • NIKAM SS, MELTZER LT: NR2B selective NMDA receptor antagonists. Curr. Pharm. Des. (2002) 8(10):845–855.
  • ••An excellent review of NR2B antagonistmedicinal chemistry research.
  • MUTEL V, BUCHY D, KLINGELSCHMIDT A et al: In vitro binding properties in rat brain of 13I-11Ro 25-6981, a potent and selective antagonist of NMDA receptors containingNR2B subunits. Neurochem. (1998) 70(5):2147–2155.
  • CHENARD BL, SHALABY IA, KOE BK et al.: Separation of aradrenergic and N-methyl-D-aspartate antagonist activity in a series of ifenprodil compounds. J. Med. Chem. (1991) 34(10):3085–3090.
  • MENNITI F, CHENARD B, COLLINS M, DUCAT M, SHALABY I, WHITE F: CP-101,606, a potent neuroprotectant selective for forebrain neurons. Eur. j Pharmacol (1997) 331(2/3):117–126.
  • BUTLER TW, BLAKE JF, BORDNER J et al.: (3R,4S)-3-14-(4-Fluoropheny1)-4-hydroxypiperidin-1-yllchroman-4,7-diol: a conformationally restricted analog of the NR2B subtype-selective NMDA antagonist (1S,2S)-1-(4-hydroxypheny1)-2-(4-hydroxy-4-phenylpiperidino)-propanol. J. Med. Chem. (1998) 41(7):1172–1184.
  • WHITTEMORE ER, ILYIN VI, KONKOY CS, WOODWARD RM: Subtype-selective antagonism of NMDA receptors by nylidrin. Eur. j Pharmacol (1997) 337(2/3):197–208.
  • TAMIZ AP, WHITTEMORE ER, ZHOU Z-L et al.: Structure-activity relationships for a series of bis(phenylalkyDamines: potent subtype-selective inhibitors of N-methyl-D-aspartate receptors. J. Med. Chem. (1998) 41(18):3499–3506.
  • GUZIKOWSKI AP, TAMIZ AP, ACOSTA-BURRUEL M et al: Synthesis of N-substituted 4-(4-hydroxyphenyl)piperidines, 4-(4-hydroxybenzyl)piperidines, and (±)-3-(4-hydroxyphenyl)pyrrolidines: selective antagonists at the 1A/2B NMDA receptor subtype./ Med. Chem. (2000) 43(5):984–994.
  • KEW JNC, TRUBE G, KEMP JA: State-dependent NMDA receptor antagonism by Ro 8-4304, a novel NR2B selective, non-competitive, voltage-independent antagonist. Br. J. Pharmacol (1998) 123(3):463–472.
  • CHAZOT PL: CP-101606 (Pfizer Inc). Curr. Opin. Invest. Drugs (2000) 1(3):370–374.
  • MENNITI FS, SHAH AK, WILLIAMS SA, WILNER KD, WHITE WF, CHENARD BL: CP-101,606: an NR2B-selective NMDA receptor antagonist. CNS Drug Rev. (1998) 4(4):307–322.
  • PINARD E, ALANINE A, BOURSON A et al.: Discovery of (R)-1-12-hydroxy-3-(4-hydroxy-pheny1)-propyll-4-(4-methyl-benzy1)-piperidin-4-ol: A novel NR1/2B subtype selective NMDA receptor antagonist. Bioorg Med. Chem. Lett. (2001) 11(10:2173–2176.
  • SCALONE M, WALDMEIER P: Efficient enantioselective synthesis of the NMDA 2B receptor antagonist Ro 67-8867. Org. Proc. Res. Dev. (2003) 7(3):418–425.
  • BORZA I, KOLOK S, GERE A et cll.: Indole-2-carboxamides as novel NR2B selective NMDA receptor antagonists. Bioorg. Med. Chem. Lett. (2003) 13(21):3859–3861.
  • TAMIZ AP, WHITTEMORE ER, WOODWARD RM, UPASANI RB, KEANA JFW: Structure-activity relationship for a series of 2-substituted 1,2,3,4-tetrahydro-9H-pyrido13,4-blindoles: potent subtype-selective inhibitors of N-methyl-D-aspartate (NMDA) receptors. Bioorg. Med. Chem. Lett. (1999) 9(11):1619–1624.
  • FARKAS S, HORVATH C, NAGY J et al: RGH-896 is a novel potent and selective NR2B-NMDA antagonist with efficacy in neuropathic pain models. Program No. 382.8. 2003 Abstract Viewer/Itinerary Planner. Washington, DC. Society for Neuroscience (2003) online.
  • MCCAULEY JA, THEBERGE CR, ROMANO JJ et al.: NR2B-selective N-methyl-D-aspartate antagonists: synthesis and evaluation of 5-substituted benzimidazoles. J. Med. Chem. (2004) 47(8):2089–2096.
  • LEIBROCK J, PROCHER H, RAUTENBERG W: EMD 95885, a new eliprodil analog with higher affinity for the N-methyl-D-aspartate (NMDA) receptor. Pharmazie (1997) 52(6):479–480.
  • WRIGHT JL, GREGORY TF, BIGGE CF et al: Subtype-selective N-methyl-D-aspartate receptor antagonists: synthesis and biological evaluation of 1-(arylalkyny1)-4-benzylpiperidines. J. Med. Chem. (1999) 42(13):2469–2477.
  • WRIGHT JL, GREGORY TF, BOXER PA et al.: Discovery of subtype-selective NMDA receptor ligands: 4-benzy1-1-piperidinylalkynylpyrroles, pyrazoles and imidazoles as NR1A/2B antagonists. Bioorg. Med. Chem. Lett. (1999) 9(19):2815–2818.
  • WRIGHT JL, GREGORY TF, KESTEN SR et al.: Subtype-selective N-methyl-D-aspartate receptor antagonists: synthesis and biological evaluation of 1-(heteroarylalkyny1)-4-benzylpiperidines. J. Med. Chem. (2000) 43(18):3408–3419.
  • KORNBERG BE, NIKAM SS, WRIGHT JL et al.: Subtype selective NMDA receptor antagonists: evaluation of some novel alkynyl analogues. Bioorg. Med. Chem. Lett. (2004) 14(5):1213–1216.
  • SCHELKUN RM, YUEN P-W, SERPA K et al.: Subtype-selective N-methyl-D-aspartate receptor antagonists: benzimidazalone and hydantoin as phenol replacements. J. Med. Chem. (2000) 43(9):1892–1897.
  • GREGORY TF, WRIGHT JL, WISE LD et aL: Parallel synthesis of a series of subtype-selective NMDA receptor antagonists. Bioorg. Med. Chem. Lett. (2000) 10(6):527–529.
  • BARTA-SZALAI G, BORZA I, BOZO E et al.: Oxamides as novel NR2B selective NMDA receptor antagonists. Bioorg. Med. Chem. Lett. (2004) 14(15):3953–3956.
  • PRO-CHER H, GOTTSCHLICH R, HASSE A, STOHER M, SEYFRIED C: (55)-3-Ary1-5-(1-piperidinylmethyl)-2-oxazolidinones, a new class of potential neuroleptics with a high affinity for sigma receptors. Bioorg. Med. Chem. Lett. (1992) 2(2):165–170.
  • WHITTEMORE ER, ILYIN VI: WOODWARD RM: Antagonism of N-methyl-D-aspartate receptors by a-site ligands: potency, subtype-selectivity and mechanisms of inhibition. J. Pharmacol. Exp. Ther. (1997) 282(1):326–338.
  • BOTTELMANN B, ALANINE A. BOURSON A et al.: 2-(3,4-Dihydro-1H-isoquinolin-2y1)-pyridines as a novel class of NR1/2B subtype selective NMDA receptor antagonists. Bioorg. Med. Chem. Lett. (2003) 13(5):829–832.
  • BOTTELMANN B, ALANINE A, BOURSON A et al.: 4-(3,4-Dihydro-1H-isoquinolin-2y1)-pyridines and 443,4-dihydro-1H-isoquinolin-2-y1)-quinolines as potent NR1/2B subtype selective NMDA receptor antagonists. Bioorg. Med. Chem. Lett. (2003) 13(10):1759–1762.
  • PINARD E, ALANINE A, BOURSON A et al.: 4-Arninoquinolines as a novel class of NR1/2B subtype selective NMDA receptor antagonists. Bioorg. Med. Chem. Lett. (2002) 12(18):2615–2619.
  • CURTIS NR, DIGGLE HJ, KULAGOWSKI JJ et al.: Novel N1-(benzyficinnamamidine derived NR2B subtype-selective NMDA receptor antagonists. Bioorg. Med. Chem. Lett. (2003) 13(4):693–696.
  • TAMIZ AP, WHITTEMORE ER, SCHELKUN RM et al.: N-(4-Hydroxyphenethyl)-4-chlorocinnamamide: a novel antagonist at the 1A/2B NMDA receptor subtype. Bioorg. Med. Chem. Lett. (1998) 8(2):199–200.
  • TAMIZ AP, CAI SX, ZHOU Z-L et al.: Structure-activity relationship of N-(phenylalkyficinnamides as novel NR2B subtype-selective NMDA receptor antagonists./ Med. Chem. (1999) 42(17):3412–3420.
  • MCCAULEY JA, THEBERGE CR, LIVERTON NJ: Chemoselective reactions of amidines: selective formation of iminopyrimidine regioisomers. Org. Lett. (2000) 2(21):3389–3391.
  • CLAIBORNE CF, MCCAULEY JA, LIBBY BE et aL: Orally efficacious NR2B-selective NMDA receptor antagonists. Bioorg. Med. Chem. Lett. (2003) 13(4):697–700.
  • BEDNAR B, CUNNINGHAM ME, KISS L et al.: Kinetic characterization of novel NR2B antagonists using fluorescence detection of calcium flux. J. Neurosci. Meth. (2004) 137(2):247–255.
  • ALANINE A. BOURSON A, BOTTELMANN B et aL: 1-Benzyloxy-4,5-dihydro-1H-imidazol-2-yl-amines, a novel class of NR1/2B subtype selective NMDA receptor antagonists. Bioorg. Med. Chem. Lett. (2003) 13(19):3155–3159.
  • DONEYAN SD, MCCABE RT: Conantokin G is an NR2B-selective competitive antagonist of N-methyl-D-aspartate receptors. MoL PharmacoL (2000) 58(3):614–623.

Websites

  • crnet.mgh.haryard.edu Spinal cord injury clinical trial

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.